Skip to main content

Table 1 Baseline characteristics of both groups (median/interquartile range)

From: Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial

Parameter

HIP

IV sucrose

p-value

Number of patients (Randomized)

18

22

 

Age(years)

76 (66–83)

66 (58–76)

0.10

Sex

Male −13 Female −5

Male −12 Female −10

0.33

Race

Caucasians −16 Africans −1 Others −1

Caucasians- 15 Africans-6 Others-1

0.12

Blood pressure (mm Hg) Systolic

130 (122–140)

131 (124–140)

0.85

Blood pressure (mm Hg) Diastolic

67 (62–75)

68 (60–72)

0.76

Hemoglobin(g/L)

110.5 (104–119)

108.5 (102–117)

0.39

Serum ferritin(ug/L)

71 (40–143)

67 (27–100)

0.59

TSAT

17 (14–20)

16.5 (10–20)

0.37

Patients on ESA*

7

6

1.0

Average ESA dose (ug/month)

60(60–80)

80(60–100)

0.20

Serum creatinine(umol/L)

246.5 (206–362)

216.5 (176–351)

0.48

Glomerular filtration rate(ml/min/1.73 m2)

20.5 (12–26)

23 (18–33)

0.39

Serum albumin

38 (35–39)

38.5 (36–41)

0.58

Intact PTH

13.05 (6.1-20.1)

13.3 (7.9-16.75)

0.93

Serum phosphate

1.28 (1.07-1.42)

1.28 (1–1.54)

0.96

Cause Of ESRD

Diabetes – 6 Ischemic nephropathy-3 Hypertension – 3 Unknown – 3 Others – 3

Diabetes −9 Ischemic nephropathy-6 Hypertension – 1 Unknown – 5 Others – 1

0.22